Financial Data and Key Metrics Changes - In 2025, the company reported revenues of $1.9 billion, primarily driven by sales of its COVID vaccine Spikevax and mNEXSPIKE [4][10] - Operating expenses decreased by $2.2 billion, or 30% year-over-year, reflecting significant cost management efforts [4] - The net loss for the year was $2.8 billion, an improvement from a net loss of $3.6 billion in 2024 [14] - Cash and investments at year-end totaled $8.1 billion, down from $9.5 billion at the end of 2024 [14][15] Business Line Data and Key Metrics Changes - The company had three products on the market in 2025: Spikevax, mNEXSPIKE, and mRESVIA, with mNEXSPIKE quickly becoming the leading product in the U.S. [7] - Total revenue for the fourth quarter was $700 million, with $300 million from the U.S. and $400 million from international markets [10] - The U.S. revenue for the full year was $1.2 billion, while international revenue was $700 million [10] Market Data and Key Metrics Changes - In the U.S., despite a decline in overall COVID market demand, the company maintained strong market share in the retail channel, particularly with mNEXSPIKE capturing 24% of the total U.S. retail market [11][25] - Internationally, revenue performance was driven by operational efficiency and vaccination rates meeting expectations [10] Company Strategy and Development Direction - The company aims for up to 10% revenue growth in 2026, primarily from international markets and local manufacturing in the U.K. and Australia [15][16] - Strategic partnerships in Latin America and Asia Pacific are expected to drive growth, alongside the anticipated launch of multiple vaccines in 2027 [20][22] - The company is focused on expanding its oncology pipeline and expects significant clinical milestones in 2026 [32] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment over the FDA's refusal to file letter regarding the flu program, highlighting regulatory uncertainty as a challenge for innovation [5] - The company remains optimistic about its growth trajectory, citing strong momentum and multiple levers for revenue growth [19][33] Other Important Information - The company has completed enrollment in several late-stage oncology studies and anticipates data readouts in 2026 [28][32] - A new Chief Development Officer has joined the company, expected to enhance the oncology pipeline [9] Q&A Session Summary Question: Implications of flu RTF on cash flow break-even guidance and INT program timing - Management is pleased with the flu filing progress in Europe and Canada, with the U.S. refile dependent on the Type A meeting with the FDA [36] - The INT program for adjuvant melanoma is event-driven, with data expected this year [40] Question: Thoughts on flu and COVID combination vaccine re-filing - The company is awaiting feedback from the FDA on what is needed for re-filing the mRNA-1010 program [43] - The phase III study for mRNA-1010 showed superior efficacy compared to standard vaccines [45] Question: European COVID vaccination market and flu vaccine strain selection - The company anticipates a larger market than the current $700 million estimate, with mNEXSPIKE expected to capture significant share [52] - Discussions on better strain matching for flu vaccines are ongoing, with strong support from international regulators [55][57] Question: Higher-than-expected cash balance explanation - The cash balance exceeded expectations due to lower cash costs and strong working capital performance [60] Question: Details on the adjuvant phase 3 melanoma study and Norovirus confidence - The adjuvant melanoma study includes interim analyses, with the first expected this year [65] - The Norovirus vaccine is targeting older adults, with a different approach than previous studies [68]

Cameco (NYSE:CCJ) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsBrian Lee - Chief Risk OfficerCory Kos - VP of Investor Relations and CommunicationsGrant Isaac - President and COOHeidi Shockey - Senior VP and CFOOrest Wowkodaw - Managing DirectorTim Gitzel - CEOConference Call ParticipantsAlexander Pearce - AnalystCraig Hutchison - Director and Base Metal AnalystLawson Winder - Equity Research AnalystMohamed Sidibe - Equity Research AnalystRalph Profiti - Managing Director and Seni ...

Beyond Air (NasdaqCM:XAIR) Q3 2026 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsBob Goodman - Chief Commercial OfficerCorey Davis - Managing DirectorDan Moorhead - CFOJason Kolbert - Director of ResearchJustin Walsh - Director of HealthcareMarie Thibault - Managing DirectorMike King - Director of ResearchSteve Lisi - CEOConference Call ParticipantsYale Chen - AnalystOperatorGood morning, and welcome everyone to Beyond Air Financial Results Call for the fiscal quarter ended December 31st, ...

CAE (NYSE:CAE) Q3 2026 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsAndrew Arnovitz - SVP, Investor Relations, and Member of CAE’s Executive Management CommitteeCalin Rovinescu - Executive Chairman of the BoardConstantino Malatesta - Interim CFOKrista Friesen - Executive Director of Equity ResearchKristine Liwag - Executive Director and Head of Aerospace & Defense Equity ResearchMatthew Bromberg - President and CEOSheila Kahyaoglu - Managing DirectorConference Call ParticipantsAnthony Val ...

Financial Data and Key Metrics Changes - In Q4 2025, sales increased by 2% to $10.8 billion, with adjusted EBIT margin expanding by 100 basis points to 7.5% [8][12] - For the full year, sales were $42 billion, slightly down due to softer volumes in North America and Europe, while adjusted EBIT margin rose by 20 basis points to 5.6% [9][12] - Adjusted EPS for Q4 rose by 29% to $2.18, and for the full year, it increased by 6% to $5.73 [8][9] - Free cash flow for the full year reached $1.9 billion, an increase of $849 million [9][18] Business Line Data and Key Metrics Changes - Three of the four segments posted higher sales year-over-year, with seating seeing an 8% increase, while complete vehicles were down 10% [16] - Body exteriors and structures, and seating segments posted strong increases in adjusted EBIT margin year-over-year [16][17] - Power and vision margins were negatively impacted by discrete items, but operational improvements are expected to drive margin expansion in 2026 [17][61] Market Data and Key Metrics Changes - Global light vehicle production was down 1% overall in Q4, with North America and China declining, while Europe saw an increase [13] - Magna's sales growth is expected to be near flat to up 3.5% in 2026, driven by new program launches and foreign currency translation benefits [21][22] Company Strategy and Development Direction - The company is focused on operational excellence initiatives, which contributed to margin expansion and are expected to continue delivering benefits in 2026 [10][27] - A disciplined approach to capital spending is emphasized, with plans to repurchase approximately 22 million shares under the NCIB [7][24] - The company aims to maintain strong free cash flow and EPS growth while reducing leverage [7][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in executing their capital allocation strategy and driving EPS growth alongside strong free cash flow [7][28] - The outlook for 2026 includes expectations for adjusted EBIT margin expansion of 40-100 basis points and free cash flow of $1.6 billion to $1.8 billion [7][22] Other Important Information - The company achieved significant operational milestones in 2025, including securing 90% of its 2028 business and receiving 151 customer awards for quality and performance [9][10] - The company has been recognized as one of the world's most ethical companies and most admired companies [11] Q&A Session Summary Question: Guidance for outgrowth ex complete vehicles of 1%-4% - Management attributed the outgrowth to operational excellence activities and new programs with favorable economic terms [31][34] Question: Operational excellence and commercial recoveries - Management indicated that operational excellence is a continuing journey with visibility on margin improvements, while commercial recoveries are expected to be neutral year-over-year [36][39] Question: Seating segment outlook and cost actions - Management confirmed that no incumbent seating programs have been lost, and the seating segment remains core and profitable despite some program roll-offs [44][46] Question: Free cash flow sustainability - Management expects free cash flow in the range of $1.6 billion to $1.8 billion to be sustainable, supported by disciplined CapEx [49] Question: Ford recall and warranty hit - Management clarified that one recall matter has been resolved, while another is ongoing, impacting margins in the power and vision segment [52][59] Question: Growth in power and vision segment - Management highlighted that growth is driven by new launches and operational improvements, with expectations for margin expansion in 2026 [61][62]

Ingersoll Rand (NYSE:IR) Q4 2025 Earnings call February 13, 2026 08:00 AM ET Company ParticipantsDavid Raso - Senior Managing Director and PartnerJeff Sprague - Founder and Managing PartnerMatthew Fort - VP of Investor RelationsNigel Coe - Managing Director and the Head of US Capital Goods Equity ResearchVicente Reynal - Chairman and CEOVik Kini - CFOConference Call ParticipantsAndrew Buscaglia - Senior Analyst for US Industrial TechnologyChris Snyder - Executive Director and Equity Research AnalystJoe O'De ...

February 13th, 2026 Greg Ebel President & CEO Pat Murray EVP & CFO Reconciliations of forward-looking non-GAAP and other financial measures to comparable GAAP measures are not available due to the challenges and impracticability of estimating certain items, particularly certain contingent liabilities and non-cash unrealized derivative fair value losses and gains which are subject to market variability. Because of those challenges, reconciliations of forward-looking non-GAAP and other financial measures are ...

YEAR END 2025 EARNINGS REPORT February 13, 2026 Safe Harbor Statement All per-share amounts in this presentation are reported on a diluted basis. The only common equity securities that are publicly traded are common shares of Eversource Energy. The earnings discussion includes financial measures that are not recognized under generally accepted accounting principles (non-GAAP) referencing earnings and EPS excluding losses associated with our previous offshore wind investments, a loss on the pending sale of t ...

CAE (NYSE:CAE) Q3 2026 Earnings call February 13, 2026 08:00 AM ET Speaker11Good day, ladies and gentlemen. Welcome to the CAE third quarter financial results for fiscal year 2026 conference call. As a reminder, all participants are in listen-only mode, and the conference is being recorded. After the presentation, there will be an opportunity for analysts to ask questions. To join the question queue, you may press Star, then one on your telephone keypad. Should you need assistance during the conference call ...

4Q2025 Supplemental Information FURNISHED AS OF FEBRUARY 12, 2026 - UNAUDITED FORWARD LOOKING STATEMENTS & RISK FACTORS This Supplemental Information report contains disclosures that are "forward-looking statements." Forward-looking statements include all statements that do not relate solely to historical or current facts and can be identified by the use of words such as "may," "will," "expect," "believe," "anticipate," "target," "intend," "plan," "estimate," "project," "continue," "should," "could," "budge ...